000165889 001__ 165889
000165889 005__ 20240229123215.0
000165889 0247_ $$2doi$$a10.3389/fphy.2020.564836
000165889 0247_ $$2altmetric$$aaltmetric:91954824
000165889 037__ $$aDKFZ-2020-02458
000165889 082__ $$a530
000165889 1001_ $$0P:(DE-He78)ca98a31afd9fff038336ecfcf56f268c$$aDal Bello, Riccardo$$b0$$eFirst author
000165889 245__ $$aProposal of a chemical mechanism for mini-beam and micro-beam efficacy
000165889 260__ $$aHeidelberg$$bSpringer$$c2020
000165889 3367_ $$2DRIVER$$aarticle
000165889 3367_ $$2DataCite$$aOutput Types/Journal article
000165889 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1607426070_24459
000165889 3367_ $$2BibTeX$$aARTICLE
000165889 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165889 3367_ $$00$$2EndNote$$aJournal Article
000165889 500__ $$a#EA:E041#LA:E041#
000165889 520__ $$aThis simulation study proposes a chemical mechanism to define a surrogate to the tumor control during micro- and mini-beam radiation therapy (MBRT). The main focus is proton-MBRT (pMBRT) and the methods developed are applied also to photon-MBRT (MRT). In both cases, the classical interpretation of physical dose cannot be used to explain the observed biological effect and a change of paradigm may be required. MBRT was reported to provide tumor control with reduced side effects when compared to standard dose delivery. The underlying mechanisms leading to a differential response of the normal tissue and the tumor are still unknown. In this work, we propose a chemical mechanism to describe the efficacy of MBRT. The model was developed starting from the observation that pMBRT led to long term survival without significant side effects of rats implanted with a high-grade glioma. We distribution of a generic radiation-induced molecule or radical could be a surrogate to describe the biological effect. The specific mechanisms leading to cell damage were outside the scope of this work. The molecules and radicals were selected according to a set of properties: (i) they should be stable to allow diffusion achieving coverage of the dose-valleys, (ii) they should reach a steady state in production versus removal, (iii) they should be a product of water radiolysis, and (iv) they should have oxidizing capacity. A convolution model was developed to assess the property (i) keeping the analysis as general as possible. The tumor coverage was defined widening the interpretation of the ICRU-62 recommendations. The properties (ii) and (iii) were investigated with the TRAX-CHEM software. The property (iv) was used to exclude not relevant chemical species. The results show that hydrogen peroxide fulfills all the requirements. Moreover, the modeling of its temporal and spatial distributions demonstrate that a uniform coverage of the target by this reactive oxygen specie (ROS) can be achieved during the beam-on time. The model was compared and proven to be compatible with three independent photon micro-beam and proton mini-beam animal experiments. We conclude that hydrogen peroxide is a good candidate to describe the mini-beam and micro-beam efficacy. Further experiments are proposed to experimentally benchmark the model and to correlate the hydrogen peroxide concentration to the tumor control probability.
000165889 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000165889 7001_ $$0P:(DE-He78)49b8eff4c466e1497028f0ad44747355$$aBecher, Tobias$$b1
000165889 7001_ $$0P:(DE-HGF)0$$aFuss$$b2
000165889 7001_ $$0P:(DE-HGF)0$$aKrämer, M.$$b3
000165889 7001_ $$0P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe$$aSeco, Joao$$b4$$eLast author
000165889 773__ $$0PERI:(DE-600)2635767-7$$a10.3389/fphy.2020.564836$$p564836$$tFrontiers of physics$$v8$$x1673-3487$$y2020
000165889 8564_ $$uhttps://www.frontiersin.org/articles/10.3389/fphy.2020.564836/full
000165889 909CO $$ooai:inrepo02.dkfz.de:165889$$pVDB
000165889 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ca98a31afd9fff038336ecfcf56f268c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000165889 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)49b8eff4c466e1497028f0ad44747355$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000165889 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000165889 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000165889 9141_ $$y2020
000165889 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-09-12$$wger
000165889 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT PHYS-BEIJING : 2018$$d2020-09-12
000165889 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-12
000165889 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-12
000165889 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-12
000165889 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-12
000165889 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2020-09-12
000165889 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-12
000165889 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-12
000165889 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-09-12
000165889 9201_ $$0I:(DE-He78)E041-20160331$$kE041$$lE041 Medizinische Physik in der Radioonkologie$$x0
000165889 980__ $$ajournal
000165889 980__ $$aVDB
000165889 980__ $$aI:(DE-He78)E041-20160331
000165889 980__ $$aUNRESTRICTED